Clinton, drugmakers agree on AIDS-med discounts; FDA wants ingredients tested for melamine;

> Former President Bill Clinton and drugmakers Pfizer and Matrix Laboratories announced a deal to lower the cost of treatments for patients with drug-resistant forms of HIV/AIDS. Report

> In a new guidance, the FDA says that certain pharmaceutical ingredients used in the manufacture or preparation of drug products should be tested for melamine. Release

> Watson Pharmaceutical got a second request from the FTC for information about the company's pending acquisition of privately held Arrow Group. Watson release

> Sanofi-Aventis started human testing of its H1N1 swine flu vaccine on Aug. 6 and filed a supplemental license application with U.S. regulators. Report

> Goldman Sachs cut its rating on Novo Nordisk to neutral from buy, saying that it's upbeat on the company's long-term outlook, but sees little short-term upside. Report

Biotech News

> The UK's Vernalis has garnered a fresh injection of cash and stands to gain more than $200 million in fees and milestones from a new research pact it forged with pharma giant GlaxoSmithKline. GSK report

> Shares of NicOx have been buoyed by the news that the French developer has reacquired the rights to an experimental glaucoma therapy that has completed--and failed--two mid-stage trials. Report

> A start-up biotech company focused on infectious diseases and founded in part by Kleiner Perkins Caufield & Byers has rounded up $30 million in new investment capital to fund its next stage of development. Report

> Novo Nordisk says that it expects the FDA to make a decision on its next-gen diabetes drug Victoza (liraglutide) in a matter of weeks. And CFO Jesper Brandgaard told Reuters that the Danish company expects a positive response. Report

And Finally... Researchers developed an animal model that provides strong evidence why the Novartis drug Gleevec helps patients with chronic myeloid leukemia survive longer, but does not keep the disease from returning if treatment ends. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.